Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique

Molecular Pharmacology

Volumn 54, Issue 1, 1998, Pages 78-85

  Willmore, E ^a   Frank, A J ^a   Padget, K ^a   Tilby, M J ^a   Austin, C A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKEMIA CELL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; TARGET CELL;

EID: 0031847082     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.1.78     Document Type: Article

References (40)

1. Austin CA and Marsh KL (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20:215-226.
2. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, and Durcacz BW (1995) Potentiation of temozolamide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72:849-856.
3. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, and Goldenberg GJ (1995) Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55:78-82.
4. Burden AD, Kingma PS, Froelich-Ammon SJ, Bjornsti M, Patchan MW, Thompson RB, and Osheroff N (1996) Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 271:29238-29244.
5. Caldecott K, Banks G, and Jeggo P (1990) DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 50:5778-5783.
6. Caldecott K, Banks G, and Jeggo P (1993) The induction and reversal of topoisomerase II cleavable complexes formed by nuclear extract from the CHO DNA repair mutant, xrs1. Mutat Res 293:259-267.
7. Cattan AR, Levett D, Douglas EA, Middleton PG, and Taylor PRA (1996) Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia. J Clin Pathol 49:848-852.
8. Charcosset J, Saucier J, and Jacquemin-Sablon A (1988) Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. Biochem Pharmacol 37:2145-2149.
9. Chaterjee S, Trivedi D, Petzold J, and Berger NA (1990) Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine-diphosphate-ribose) synthesisdeficient V79 Chinese hamster cell lines. Cancer Res 50:2713-2718.
10. Chen C, Fuscoe JC, Liu Q, and Relling MV (1996) Etoposide causes illegitimate V (D) J recombination in human lymphoblastoid leukemic cells. Blood 88:2210-2218.
11. Chresta CM, Masters JRW, and Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56:1834-1841.
12. Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA, and Capranico G (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Mol Pharmacol 50:1463-1471.
13. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869.
14. Dereuddre S, Frey S, Delaporte C, and Jacquemin-Sablon A (1995) Cloning and characterisation of full-length cDNAs coding for the DNA topoisomerase IIβ from Chinese hamster lung cells sensitive and resistant to 9-OH-ellipticine. Biochim Biophys Acta 1264:178-182.
15. Drake FH, Hofmann GA, Bartus HF, Mattern MA, Crooke ST, and Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154-8160.
16. Frank AJ, Proctor SJ, and Tilby MJ (1996) Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells. Blood 88:977-984.
17. Houlbrook S, Addison CM, Davies SL, Carmichael J (1995) Stratford IJ, Harris AL, and Hickson ID. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72:1454-1461.
18. Hsiang Y and Liu LF (1989) Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J Biol Chem 264:9713-9715.
19. Joel S (1996) The clinical pharmacology of etoposide: An update. Cancer Treat Rev 22:179-221.
20. Kalwinsky DK, Look AT, Ducore J, and Fridlans A. (1983) Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43:1592-1597.
21. Kamesaki S, Kamesaki H, Jorgenson TJ, Tanizawa A, Pommier Y, and Cossman J (1993) bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251-4256.
22. Kaufmann WK, Boyer JC, Estabrooks LL, and Wilson SJ (1991) Inhibition of replicon initiation in human cells following stabilisation of topoisomerase-DNA cleavable complexes. Mol Cell Biol. 11:3711-3718.
23. Liu LF, Liu CC, and Alberts BM (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double strand break. Cell 19:697-707.
24. Long BH, Musiai ST, and Brattain MG (1985) Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45:3106-3112.
25. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, and Casazza A (1991) Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51:5275-5284.
26. Lorico A, Rappa G, Srimatkcandada S, Catapano CV, Fernandes DJ, Germino JF, and Sartorelli AC (1995) Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 55:4352-4360.
27. Marsh KL, Willmore E, Tinelli S, Cornarotti M, Meczes E (1996) Capranico G, Fisher LM, and Austin CA. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β. Biochem Pharmacol 52:1675-1685.
28. Meczes EL, Marsh KL, Fisher LM, Rogers MP, and Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
29. Mirski SEL, Evans CD, Almquist KC, Slovak ML, and Cole S (1993) Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53:4866-4873.
30. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of religation by etoposide. Biochemistry 28:6157-6160.
31. Patel S, and Fisher LM (1993) Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer 67:456-463.
32. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542.
33. Qiu J, Catapano V, Fernandes DJ (1996) Formation of topoisomerase IIα complexes with nascent DNA is related to VM-26 induced cytotoxicity. Biochemistry 35:16354-16360.
34. Ritke MK, Roberts D, Allan JR, Bergoltz VV, and Yalowich JC (1994) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer 69:687-697.
35. Robinson MJ and Osheroff N (1991) Effects of antineoplastic drugs on the poststrand passage DNA cleavage/religation equilibrium of topoisomerase II, Biochemistry 30:1807-1813.
36. Sehested M and Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, Clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51:879-886.
37. 2 to M transition: implications for gene therapy. Cancer Res 57:818-823.
38. Suzuki H, Tarumoto Y, and Ohsawa M (1997) Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations. Mutagenesis 12:29-33.
39. Vega MC, Coll M, and Aleman C (1996) Intrinsic conformational preferences of the Hoechst dye family and their influence on DNA binding. Eur J. Biochem 239:376-383.
40. Wang JC (1996) DNA Topoisomerases. Ann Rev Biochem 65:635-692.